Group 1 - The core viewpoint of the article highlights that the investment and financing activities in China's biotechnology breeding industry have shown a trend of initial volatility followed by a decline, with 2022 being the most active year in terms of both the number of investment events and the total investment amount, reaching 24.58 billion RMB [1][2] - The single financing events in the biotechnology breeding sector have exhibited a fluctuating downward trend, peaking in 2024 with a single financing amount of 3.54 billion RMB [2] - The financing rounds in the biotechnology breeding field are predominantly in the early stages, with the most events occurring in the A round and angel round, each having 5 events from 2015 to 2025 [4] Group 2 - The investment events in the biotechnology breeding industry are most concentrated in Guangdong, followed by Beijing and Jiangsu, with Guangdong accounting for 9 events from 2015 to 2025, while other provinces remain relatively inactive [7] - The capital market shows a greater emphasis on investments in the animal breeding sector due to the higher commercialization maturity of plant breeding compared to the relatively lagging technological research and industrial development in animal breeding [10] - The main investors in the biotechnology breeding industry are primarily investment firms, with notable representatives including SoftBank China Capital and Shenzhen Capital, while industrial investors include Tongwei Co. and Guangdong Seed Industry Group [12] Group 3 - The biotechnology breeding industry has seen horizontal mergers and acquisitions as a primary strategy for companies to expand their scale, with notable examples including Fengle Seed Industry's acquisition of Tianyu Xinghe in March 2022 to enhance innovation in breeding technology [15] - A summary of mergers and acquisitions in the biotechnology breeding sector since 2021 indicates that midstream companies are the main participants, focusing on horizontal expansion and diversification of business [15][17]